Jiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
Jiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
Bioorg Med Chem Lett. 2020 May 15;30(10):127118. doi: 10.1016/j.bmcl.2020.127118. Epub 2020 Mar 19.
Fatty acid amide hydrolase (FAAH) is a promising target for the development of drugs to treat pain, inflammation, and other central nervous system disorders. Herein, a series of novel heterocyclic carbohydrazide derivatives were firstly designed by the classic scaffold-hopping strategy. Then, multi-steps synthesis and human FAAH enzyme inhibiting activity assays were conducted. Among them, compound 26 showedstrong inhibition against human FAAH with IC of 2.8 μM. Corresponding docking studies revealed that the acyl hydrazide group of compound 26 well-occupied the acyl-chain binding pocket. It also exhibited high selectivity towards FAAH when comparing with CES2 and MAGL. Additionally, compound 26 effectively suppressed the LPS-induced neuroinflammation of microglial cells (BV2) via the reduction of interleukin-1β and tumor necrosis factor-α. Our results provided significative lead compounds for the further discovery of novel selective and safe FAAH inhibitors with potent anti-neuroinflammation activity.
脂肪酸酰胺水解酶(FAAH)是开发用于治疗疼痛、炎症和其他中枢神经系统疾病的药物的一个有前途的靶点。在此,我们首次通过经典的骨架跳跃策略设计了一系列新型杂环碳酰肼衍生物。然后,进行了多步合成和人 FAAH 酶抑制活性测定。其中,化合物 26 对人 FAAH 表现出强烈的抑制作用,IC 为 2.8 μM。相应的对接研究表明,化合物 26 的酰基酰肼基团很好地占据了酰基链结合口袋。与 CES2 和 MAGL 相比,它对 FAAH 也表现出高选择性。此外,化合物 26 通过降低白细胞介素-1β和肿瘤坏死因子-α,有效抑制脂多糖诱导的小胶质细胞(BV2)的神经炎症。我们的研究结果为进一步发现具有潜在抗神经炎症活性的新型选择性和安全 FAAH 抑制剂提供了有意义的先导化合物。